"Charles River's tools make it easier and more efficient to discover new drugs," Cramer added. "And they enable their clients to more quickly decide whether an early-stage compound is worth trying to develop."
"Plus, as biopharma companies outsource more and more of their lab work, Charles River sees a major opportunity to take share over the next several years."
"If drug companies outsource to us we can do the work as fast or faster, as well or better and always a lot a lower price point because our facilities are built for efficiency," explained James Foster, the Chairman and CEO of Charles River Laboratories on Mad Money.
Although the stock has shot up more than 20% in 6 months, and climbed 5% in only the past week, Cramer thinks it could have more upside. "I like the current posture. It's a good company. And I think the latter part of 2013 will be big for them."
These Stocks Don't Stay Down Long, Says Cramer